Alnylam Reports Results of Lumasiran in P-III ILLUMINATE-B Study for Primary Hyperoxaluria Type 1 in Children Under the Age of Six

 Alnylam Reports Results of Lumasiran in P-III ILLUMINATE-B Study for Primary Hyperoxaluria Type 1 in Children Under the Age of Six

Alnylam Reports Results of Lumasiran in P-III ILLUMINATE-B Study for Primary Hyperoxaluria Type 1 in Children Under the Age of Six

Shots:

  • The P-III ILLUMINATE-B study involves assessing Lumasiran in 18 patients with PH1 under the age of 6 (3-72mos.), with an eGFR >45 mL/min/1.73 m2 or normal serum creatinine if less than 12mos. old at 9 study sites in 5 countries across the globe
  • The study demonstrated a reduction in the hepatic production of oxalate across all ages, safety & tolerability profile is consistent with that observed in P-III ILLUMINATE-A study. The study also demonstrated positive results across 2EPs, including additional measures of urinary and plasma oxalate
  • Lumasiran (SC) RNAi therapeutic targeting HAO1 in development for the treatment of PH1 and has received the US FDA’s ODD & BT in addition to EMA’s ODD and PRIME designation

Click here ­to­ read full press release/ article | Ref: Alnylam | Image: Alnylam

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post